RHOJ derived peptide promotes chemosensitivity by inhibiting glutamine metabolism in gastric cancer

Key Points

• Inhibiting glutamine metabolism increases chemosensitivity in gastric cancer cells, promoting better treatment outcomes.
• The study reveals that the peptide derived from RHOJ plays a critical role in enhancing drug effectiveness in this cancer type.
• Experimental approaches demonstrated that the peptide significantly alters metabolic pathways related to glutamine in gastric cancer.
• This research supports the potential of targeting glutamine metabolism for improving treatment strategies in gastric cancer, warranting further investigation.